EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57

Abstract

PRIMARY PLASMA CELL LEUKAEMIA

*Abotaleb Alia A. MD

ABSTRACT

Background: Plasma cell leukemia (PCL) is a rare and aggressive form of plasma cell disorder characterized by the presence of circulating plasma cells. It is classified as either primary PCL (pPCL) or as secondary PCL (sPCL). Intensive chemotherapy regimens and bortezomib-based regimens are recommended followed by high-dose therapy with autologous stem-cell transplantation (HDT/ASCT) if feasible. Because the incidence of PCL is relatively low and fulminant presentation, we are reporting this case. Case Summery: A 52-year-old Saudi woman with a history of hypertension, diabetes mellitus, dyslipidemia and morbid obesity presented with symptoms of anemia and recurrent community acquired pneumonia.Laboratory evaluation showed normocytic anemia, leukocytosis with 46% atypical lymphocytes, and normal platelets. Peripheral smear and flow cytometry confirmed PCL with 30% plasma cells. Bone marrow biopsy demonstrated 50% plasma cells (38+, 138+, 117+, 10-, 19-, 20-, 56-) and hypercellularity. Fish on bone marrow showed p53 in 40% of cells, deletion 13q in 30% of cells, duplication 1q and deletion 1p.VCD therapy was started then upgraded to VD-PACE regimen to be followed by autologous bone marrow transplantation but unfourtionatly deteriorated and died due to septic shock and multi-organ failure. Conclusion: PCL is the most aggressive variant of monoclonal gammopathy that carry a poor prognosis despite of all available treatment modalities. From what described in the literatures and by looking to our case, pPCL sometimes is difficult to be differentiated from sPCL, so we need more biological and immunohistochemistry tools in addition to more molecular studies to help in distinguish between these two forms. Multi-center studies and clinical trials should be conducted to develop accurate criteria for the early diagnosis and prompt treatment of this disease.

Keywords: Case report, multiple myeloma, plasma cell leukemia, VD-PACE, VCD, ASCT.


[Full Text Article]

INDEXING

NEWS & UPDATION

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 September 2022 Issue has been Published, Kindly check it on https://www.ejpmr.com/issue

  • EJPMR: SEPTEMBER ISSUE PUBLISHED

    SEPTEMBER Issue has been successfully launched on 1 September 2022.

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database